- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Aptamer-Drug Conjugate (ApDC) Development Services
- Nuclide Nucleic Acid Aptamer Screening Service
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Peptide Affinity Maturation Services
- Peptide-Drug Conjugate (PDC) Development Services
- Stapled Peptide Development Services
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Antibody Production Services
- mRNA Immunogen Production Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Recombinant Expression Strategies for Bispecific Antibodies: What You Need to Know？
- Antibody Engineering and Modification: Maximizing Therapeutic and Diagnostic Utility
- Bispecific Antibodies (bsAbs): Mechanisms of Action Explained
- Applications of bispecific antibodies in cancer therapy
- Beyond PD-1 Blockade: How BiCE Bridges T Cells and cDC1s to Unlock Cold Tumors
- From Purity to Functionality: A Comprehensive Guide to Recombinant Antibody Quality Control Standards
- How much do you know about the molecular design and mechanism of action of ADC drugs?
- The ADC linker serves as a crucial "bridge" component.
- ADCs are becoming increasingly mature in the field of tumor therapy.
- Cracking the Immune System’s “Source Code”: Why Is B-Cell Technology the Ultimate Path to Antibody Discovery?
Special topic on antibody modification
- High-Throughput Yeast Display Platform for Macrocyclic Peptide Discovery
- How Are Antibody Drugs Produced? A Deep Dive into Mammalian Cell Culture and Purification Processes
- Expression of Recombinant Antibodies in Mammalian Cells: Core Technologies – Comprehensive Analysis of Host Selection and Purification Strategies
- Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?
- Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor
- Construction of yeast hybrid library: Gateway technology
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
Yeast Display Technology Special Topic
- Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology
- Rationale and Significance of Bispecific Antibody Development
- Protein Not Expressing? You Might Have Chosen the Wrong Tag!
- What to Do After Protein Purification? These Four Validation Methods You Must Know!
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
Antibody Detection Service Topic
- Frontiers in Targeted Drug Development: Comparison and Application of Various Peptide Screening Methods
- Application of phage display (Part 2)
- Application of phage display (Part 1)
- Phage Display
- Technical Article: Detailed Guide to Phage Screening
- Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods
- Revolutionary Advances in Single-Domain Antibody Development and Applications
- New Method for Discovering Targeted Drugs: Screening of Peptide Libraries Based on Phage Display Technology
- How much do you know about IgG, Fab, scFv, and VHH?
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
Special Topic on Phage Display Technology
- CD7-targeted Antibody-Drug Conjugates: A New Hope for T-Cell Acute Lymphoblastic Leukemia
- Discovery of targeted nucleic acid small molecules: Cell-SELEX technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- In Vivo Screening Services – Animal Models
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
Molecular Biology Service Topics
-
Product Center
- Contact Us
The efficacy and safety of ADC are determined by antibodies Linker、 The three core components of the load are jointly determined. Faced with the challenges of tumor heterogeneity and drug resistance, dual loading and dual specificity ADC design provide a new solution path. Tek Biotech relies on a dual display technology platform to provide a full process ADC development solution from antibody screening to linker design and customized coupling, empowering the research and development of next-generation precision drugs.\n
From PD-1 inhibitors to TNF-α antagonists, explore the complete manufacturing workflow of complex antibody drugs. Learn why mammalian cells (CHO/HEK293) are essential, upstream cell line development, downstream Protein A affinity purification, and viral clearance processes.
In the development of antibody drug conjugates (ADCs), people often focus on the precise targeting of antibodies and the powerful killing power of payloads. However, it is often the unknown 'linker' that determines the safety, stability, and upper limit of efficacy of ADC. This article delves into how Linker balances hydrophilicity and hydrophobicity, accurately controls the release of payloads, and addresses chemical challenges in purification and large-scale production, bringing new breakthroughs to ADC development.\n
Overview of mammalian host selection (CHO, HEK293) and downstream purification processes (Protein A, ion exchange, HIC) for high-quality recombinant antibody production.
Comparison of phage display, mRNA display, and peptide chip technologies for targeted therapeutic peptide discovery and optimization.
ADCs combine antibody specificity with cytotoxic payloads to treat hematologic and solid tumors. With diverse antigens, cleavable linkers, and novel payloads, they enhance efficacy. Toxicity management and novel formats remain key for expanding ADC applications.
CD7-ADC delivering BCL-XLi shows potent anti-T-ALL activity, spares platelets, and synergizes with venetoclax.
By comparing the principles, performance, and applicable scenarios of the three major display technologies—phage, yeast, and mRNA—we analyze the strengths and weaknesses of each technology in terms of library capacity, protein folding, and screening cycles. Leveraging its mature display technology platform, TekBio provides one-stop services for the development of various types of monoclonal antibodies and antibody optimization.
Antibodies derived from animal models are prone to ineffectiveness in humans and immune reactions, primarily due to their exogenous nature. Leveraging the immunological advantages of human B cells—such as natural antigen recognition and affinity maturation—Super SingleB? technology enables the efficient screening of high-quality fully human antibodies. TechBio has established a dedicated platform to provide one-stop antibody development services.
This article introduces applications of PhagePro Tech? phage display platform in peptide lead discovery, gene/cell therapy and diagnostic reagents. It describes screening strategies for penetrating/targeting peptides, phage-mediated bacterial gene delivery, CAR-T antibody screening and phage-based pathogen detection, and introduces Tek Biotechnology’s full-service antibody development platform.
